DIOSynVax

News

An AI-powered universal vaccine tech developed by UK biotech DIOSynVax has shown preliminary efficacy in a world-first human trial.

News

Fresh from an alliance with Novartis, Chai Discovery has raised $400 million in third-round funding for its AI-based molecular design platform.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.